ABI
CYTO

Adamant Biomedical Investments’s Altamira Therapeutics Ltd CYTO Stock Holding History

Adamant Biomedical Investments’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$8.46M Hold
27
– – 2.02% 14
2014
Q3 		$10M Buy
+27
New +$13.4M 2.5% 9

Other funds holding CYTO

CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Adamant Biomedical Investments's CYTO Position: Q4 2014 in Review

Adamant Biomedical Investments held its Altamira Therapeutics Ltd (CYTO) position steady in Q4 2014 at 27 shares worth $8.46M. The position accounts for 2.02% of the portfolio, ranked #14.

Adamant Biomedical Investments first reported a position in CYTO in Q3 2014 and has held it in 2 quarters since. The position peaked at $10M in Q3 2014. 6 funds tracked by Wall St. Rank hold CYTO as of Q4 2014.

  • Adamant Biomedical Investments held 27 shares of Altamira Therapeutics Ltd worth $8.46M as of Q4 2014.
  • Adamant Biomedical Investments left its Altamira Therapeutics Ltd share count unchanged in Q4 2014.
  • Altamira Therapeutics Ltd made up 2.02% of Adamant Biomedical Investments's portfolio in Q4 2014, its #14 holding.
  • Adamant Biomedical Investments first reported a position in Altamira Therapeutics Ltd in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's Altamira Therapeutics Ltd position peaked at $10M in Q3 2014.
  • 6 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.